INVITAE CORP. overview

Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire SAN FRANCISCO, April 11, 2024 – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, today announced new studies to be presented at the American Society of Breast Surgeons Annual Meeting (ASBrS) held in Orlando from April 10-14, 2024 . The...

Invitae Launches Update to Invitae Generation™: Clinical Variant Modeling Improves Variant Classification PR Newswire SAN FRANCISCO, March 12, 2024 – An Invitae-developed innovative approach to help reduce variants of uncertain significance – SAN FRANCISCO , March 12, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, today announced the launch of an update to Invitae Generation™ with Clinical Variant Modeling, a novel machine learning approach designed to aid...

Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results PR Newswire SAN FRANCISCO, March 6, 2024 SAN FRANCISCO , March 6, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, today announced estimated unaudited fourth quarter and full year 2023 revenue, gross profit and cash burn. Estimated unaudited financial results for fourth quarter 2023 Fourth quarter 2023 revenue was $127.8 million , an increase of approximately 4% from a year ago....

Invitae to Present Data at the 2024 ACMG Annual Clinical Genetics Meeting PR Newswire SAN FRANCISCO, March 5, 2024 – Announcing Invitae Generation™, a high-quality variant detection and classification platform – SAN FRANCISCO , March 5, 2024 /PRNewswire/ -- Researchers from Invitae (OTC: NVTA), a leading medical genetics company, are showcasing their work next week at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada from...

Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process PR Newswire SAN FRANCISCO, Feb. 13, 2024 – Company to Use its Cash on Hand to Operate its Business During the Proceedings and Continues to Serve Customers and Patients – SAN FRANCISCO , Feb. 13, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, announced today that it is building on previous actions to manage costs and improve its business structure by filing for voluntary chapter 11...

Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics PR Newswire SAN FRANCISCO, Jan. 30, 2024 SAN FRANCISCO , Jan. 30, 2024 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, designed to advance genetics-based drug discovery for rare diseases. The goal of...

Invitae Completes Sale of Reproductive Health Assets to Natera PR Newswire SAN FRANCISCO, Jan. 22, 2024 SAN FRANCISCO , Jan. 22, 2024 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has completed the sale of certain reproductive health assets, which include carrier screening and non-invasive prenatal screening, to Natera (NASDAQ: NTRA). The value of the transaction is up to $52.5 million , including cash, milestone payments and litigation credits....

Invitae Divests Ciitizen Health Data Platform and Implements Further Cost Cuts PR Newswire SAN FRANCISCO, Dec. 13, 2023 – Maintains Minority Equity Stake in Ciitizen – – Anticipated Total Cash Savings of Approximately $90 -100 Million on an Annualized Basis – SAN FRANCISCO , Dec. 13, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced strategic changes to streamline operations and reduce operating cash burn. The company has divested the assets...